Australia Weighs Paid Reproductive Leave as the Employment Standards Inquiry Tests Sick Leave

Australia's National Employment Standards are under scrutiny in a federal inquiry examining whether the current minimum safety net still fits the realities of modern working life. Unions, lawyers and health advocates have used their submissions to argue for a new entitlement: at least ten days of non-cumulative paid reproductive leave, sitting alongside existing sick leave rather than replacing it.

The inquiry is expected to report later in 2026, and its findings could reshape how millions of Australian workers manage fertility treatment, miscarriage, menstrual pain, menopause and endometriosis.

The debate is grounded in individual testimony rather than abstraction. Georgia, a graphic designer in her twenties, told the inquiry she took only two days off after a miscarriage at thirteen weeks earlier this year, describing the episode as emotionally traumatic. Her workplace, she said, had no written policy on miscarriage.

She also reported regular menstrual pain but felt unable to take leave for it, and would invent another reason if she needed a day away from work. Such accounts illustrate a gap between formal entitlements and lived experience.

What makes the Australian case instructive is that the policy is not hypothetical. Queensland public sector workers already receive ten days of paid reproductive health leave, and some private employers have introduced menstrual and reproductive health leave or flexible arrangements.

Internationally, Spain introduced paid menstrual leave in 2023 as the first European country to do so, while Japan has had menstrual leave provisions since 1947, though without guaranteed pay or a fixed number of days. Indonesia, South Korea, Zambia and several Mexican states also operate menstrual leave policies.

TL;DR A federal inquiry is testing whether Australia's National Employment Standards should include at least ten days of non-cumulative paid reproductive leave, additional to sick leave. Submissions from unions, lawyers and advocates argue the entitlement should cover fertility treatment, miscarriage, menstrual pain, menopause and endometriosis, with some proposing coverage for men through prostate screening and vasectomies. Queensland's public sector already grants ten days, and employers such as INBLUEM report productivity gains from cycle-aware flexibility. Spain, Japan, Indonesia, South Korea, Zambia and several Mexican states offer comparative precedents, giving the inquiry a substantial evidence base ahead of its 2026 report.

The Case for a Standalone Reproductive Leave Entitlement

The central argument before the inquiry is structural rather than sentimental. Advocates contend that sick leave is a poor fit for predictable, recurring biological events, because workers ration it against ordinary illness and often conceal the real reason for absence.

A dedicated, non-cumulative entitlement of at least ten days would separate reproductive health from general sickness and remove the incentive to fabricate explanations. The design matters as much as the principle: non-cumulative leave resets annually, preventing hoarding, while additionality preserves sick leave for its intended purpose.

Why Sick Leave Fails as a Substitute

Sick leave is nominally universal but practically conditional. Workers weigh each absence against future illness, workplace norms and managerial discretion, and reproductive health events lose that calculation more often than not.

Georgia's account is emblematic: two days taken after a thirteen-week miscarriage, no written policy, and a habitual alternative excuse for menstrual pain. The result is presenteeism, where employees attend work while unwell, and the productivity cost is borne quietly by employers who never measure it.

The inquiry's submissions extend the proposed coverage well beyond menstruation. Fertility treatment, miscarriage, menopause and endometriosis all involve scheduled appointments, unpredictable symptom flares and recovery periods that standard sick leave handles awkwardly. Endometriosis in particular produces chronic, episodic pain that can require repeated short absences rather than one continuous block.

A fixed annual allocation with clear eligibility criteria gives workers and managers a shared reference point, reducing negotiation and discretion at the point of need.

Additionality is the contested design feature. Employers may view a new ten-day entitlement as a straightforward cost increase, while advocates argue it displaces informal arrangements that already exist in practice. The Queensland public sector precedent offers a natural experiment: ten days of paid reproductive health leave operating within an existing industrial framework.

If absence data and retention outcomes there prove stable, the fiscal objection weakens considerably, and the inquiry gains an Australian evidence base rather than relying solely on overseas comparisons.

Coverage for men is a further dimension that reframes the policy as universal rather than gender-specific. Submissions propose that reproductive leave extend to prostate cancer screening and vasectomies, which would make the entitlement available across the workforce and reduce the risk of it being stigmatised as a women's issue.

Universal eligibility also simplifies administration, since employers apply one policy rather than adjudicating which conditions qualify and which do not.

Design Questions the Inquiry Must Resolve

Three design questions dominate the technical debate. First, whether the entitlement is non-cumulative, which prevents annual hoarding but penalises workers whose conditions flare irregularly. Second, whether it is additional to sick leave or carved from a combined pool, a distinction that determines real cost.

Third, whether eligibility requires medical certification, which improves integrity but adds friction and disclosure burdens for conditions many workers prefer to keep private.

Employer flexibility is the softer complement to statutory leave. Submissions argue that workplaces should offer adjustable hours, remote work and predictable scheduling alongside any new entitlement, since a leave day is a blunt instrument for a symptom that may last three hours.

The combination of a fixed allocation and flexible arrangements addresses both the acute and the chronic dimensions of reproductive health, and it distributes the adjustment burden between statute and workplace practice.

Enforcement and record-keeping present practical complications. A non-cumulative entitlement requires payroll systems to track a separate balance, and small employers without dedicated human resources functions may struggle with compliance.

The inquiry will need to weigh administrative simplicity against the precision that advocates want, and it may look to Queensland's public sector implementation for guidance on how the entitlement is recorded, audited and reported in practice.

Finally, the inquiry must decide whether reproductive leave belongs in the National Employment Standards at all, or whether it should be pursued through enterprise agreements and industry awards. Placing it in the NES creates a universal floor; leaving it to bargaining allows variation but produces uneven coverage.

The choice determines whether the policy reaches the low-paid, casualised and small-business workforces that currently have the least access to flexible arrangements.

Employer Experience and the Productivity Argument

The employer side of the evidence is thinner than the advocacy side but more operationally specific. Montana Lower, founder of natural skincare business INBLUEM in regional New South Wales, told the inquiry that staff can use flexible working arrangements and can voluntarily share cycle dates through a team calendar filter.

She reported that accommodating the menstrual cycle increased productivity and improved how staff feel at work. The claim is modest but consequential: it frames reproductive health policy as workforce management rather than welfare.

Cycle-Aware Scheduling in Practice

INBLUEM's approach relies on voluntary disclosure and a calendar filter, which lets employees flag expected low-energy days without explaining symptoms to a manager. The mechanism is opt-in, so privacy is preserved by default, and it produces scheduling data that supervisors can use for task allocation.

Whether such systems scale beyond small businesses is uncertain, but they demonstrate that the operational barrier is design rather than principle.

The productivity argument requires careful handling. Self-reported improvements in how staff feel at work are not the same as measured output, and the inquiry should treat founder testimony as indicative rather than conclusive.

Still, the direction of the claim aligns with broader evidence on presenteeism, where unwell employees attend work at reduced effectiveness. If reproductive leave converts concealed absence into managed absence, the net effect on output may be positive even after accounting for the leave itself.

Small and medium enterprises face disproportionate friction. A ten-day entitlement per worker is easier to absorb in a large firm with pooled coverage than in a business where one absence disrupts a single shift.

The inquiry may therefore consider phasing, exemptions or subsidised coverage for small employers, mirroring how other leave entitlements are sometimes cushioned. Without such provisions, the policy risks concentrating costs on the businesses least able to plan around them.

Managerial capability is the quiet variable. A written policy only works if supervisors apply it without requiring justification, and Georgia's experience suggests the gap sits at the front line rather than in the statute book.

Training, template conversations and clear escalation routes may matter as much as the number of days granted, and the inquiry's recommendations would be stronger for addressing implementation culture alongside entitlement design.

Cost, Coverage and the Small Business Question

Cost estimates for a universal ten-day entitlement depend heavily on take-up. If reproductive leave substitutes for sick leave already being used, the incremental cost is administrative rather than fiscal; if it is genuinely additional, employers absorb ten new paid days per worker annually.

The inquiry's modelling will need to distinguish substitution from addition, and the Queensland experience offers the closest available proxy for take-up rates in a comparable workforce.

Casual and contract workers sit outside the standard leave framework entirely, and any NES amendment would need to address how they are covered. A non-cumulative entitlement assumes an ongoing employment relationship with an annual cycle, which casual engagement does not provide.

Without a specific mechanism, the workers most exposed to income loss from reproductive health events would remain the least protected, undermining the policy's stated purpose.

Industry variation also matters. Shift-based sectors such as hospitality, healthcare and logistics cannot easily absorb unplanned absences, and their scheduling constraints differ from office environments where remote work provides a buffer.

A single national standard may therefore require sector-specific guidance on rostering and replacement, or the flexibility component may need to carry more weight in those industries than the leave component.

Compliance monitoring is the final cost consideration. A new entitlement requires payroll configuration, manager training, record-keeping and dispute resolution pathways, all of which carry fixed costs that fall hardest on small employers.

The inquiry could recommend a transition period, model policies and a template clause for enterprise agreements, reducing the implementation burden while preserving the substance of the entitlement.

International Precedents and What They Reveal

Comparative evidence gives the inquiry a useful map of what has been tried and where the design choices diverge. Spain introduced paid menstrual leave in 2023, becoming the first European country to do so, and its experience will be watched for take-up and employer response.

Japan has maintained menstrual leave provisions since 1947, but the leave is not guaranteed to be paid and the number of days is not fixed, which limits its value as a model for a paid Australian entitlement.

Divergent Models Across Jurisdictions

Japan's long-running provision illustrates the weakness of an unpaid, unspecified entitlement. Without guaranteed pay or a defined allocation, the policy exists formally but delivers little practical protection, and take-up is understood to be low.

The lesson for Australia is that statutory recognition alone is insufficient; the entitlement must be paid, bounded and additional to existing leave to change behaviour at the workplace level.

Spain's 2023 reform takes the opposite approach, embedding paid menstrual leave in national law with medical certification requirements. The certification condition has attracted criticism because it forces disclosure and depends on a doctor's confirmation of symptoms that are difficult to verify objectively.

Australia's inquiry will need to decide whether certification improves integrity enough to justify the friction and privacy cost it imposes on workers.

Indonesia, South Korea, Zambia and several Mexican states complete the comparative picture, each with different entitlement lengths and payment rules. The variation across these jurisdictions suggests there is no settled international standard, only a family of approaches.

Australia's federal structure adds a further layer, since Queensland already operates a public sector scheme that could either be extended nationally or left as a state-level precedent.

The broader trend is toward recognising menstrual and reproductive health as a workplace issue rather than a private matter. That shift is recent in most jurisdictions, and the evidence base on outcomes remains thin.

The inquiry's 2026 report could therefore contribute original findings, particularly if it draws on Queensland's administrative data rather than relying on international comparisons alone.

Lessons for Australia's Federal Inquiry

The clearest lesson from comparative evidence is that payment and definition determine effectiveness. Japan's provision has existed for more than seven decades without guaranteed pay or a fixed allocation, and its practical reach is limited.

Spain's paid model is too recent for outcome data, but its certification requirement illustrates the trade-off between integrity and privacy. Australia can design around both weaknesses by making the entitlement paid, bounded and non-cumulative.

A second lesson concerns universality. Jurisdictions that frame menstrual leave narrowly as a women's provision risk stigma and uneven take-up, whereas male-inclusive coverage for prostate screening and vasectomies normalises the entitlement across the workforce.

The submissions before the inquiry already propose this extension, and adopting it would align Australia with the broader principle that reproductive health is a general workplace concern rather than a gender-specific concession.

A third lesson is that statutory leave and workplace flexibility are complements, not substitutes. INBLUEM's cycle calendar and Queensland's ten-day entitlement address different problems: one manages predictable variation, the other covers acute events.

A national standard that mandates leave while encouraging flexible arrangements would capture both, and the inquiry's recommendations would be more durable for treating them as a package rather than competing options.

The inquiry's 2026 report will therefore be judged on design detail rather than principle. Whether the entitlement is additional to sick leave, whether it is non-cumulative, whether certification is required, how casual workers are covered and how small employers are supported will determine whether the policy changes behaviour.

The evidence base exists; the remaining task is calibration, and the Queensland precedent provides the most direct Australian test of what works.

What the Inquiry's 2026 Report Will Decide

The federal inquiry's report, expected later in 2026, will determine whether reproductive leave becomes a universal minimum standard or remains a patchwork of public sector schemes and voluntary employer policies.

The submissions have established the case for a paid, non-cumulative entitlement of at least ten days, additional to sick leave, covering fertility treatment, miscarriage, menstrual pain, menopause and endometriosis. The unresolved questions are design and coverage, not principle.

Balancing Evidence, Cost and Fairness

Cost modelling will be central. The inquiry must distinguish substitution from addition, estimate take-up using Queensland's administrative data, and account for the fixed compliance costs that fall on small employers.

A policy that looks affordable in aggregate can still be unworkable for a business where one absence disrupts a single shift, and the recommendations should reflect that asymmetry rather than assuming uniform capacity.

Fairness considerations cut in two directions. A universal NES entitlement protects low-paid and casualised workers who currently have the least access to flexible arrangements, but a poorly designed casual mechanism could leave them outside coverage entirely.

The inquiry's credibility will depend on whether it addresses the workers most exposed to income loss, rather than designing for the office-based workforce that already has informal flexibility.

Privacy is the third axis. Medical certification improves integrity but forces disclosure of conditions many workers prefer to keep private, and Georgia's account shows that stigma operates at the front line even without formal requirements.

A voluntary disclosure model, combined with a non-cumulative allocation that does not require justification, may achieve more practical protection than a certified scheme that workers avoid using.

Implementation and the Road Ahead

Implementation will require more than a statutory amendment. Payroll systems need a separate balance, managers need training on applying the entitlement without interrogation, and enterprise agreements need template clauses that align with the new standard.

The Queensland public sector scheme offers a working model for each of these elements, and extending it nationally would be less disruptive than designing from scratch.

Employer flexibility should be treated as part of the package rather than an alternative to leave. Cycle-aware scheduling, adjustable hours and remote work address the predictable dimension of reproductive health, while the statutory entitlement covers acute events.

Together they reduce presenteeism, improve retention and give workers a practical alternative to inventing reasons for absence, which is the outcome Georgia's testimony most clearly demands.

The international comparison suggests Australia has room to lead. Spain's paid model is recent, Japan's unpaid provision is weak, and most other jurisdictions offer partial coverage. A paid, bounded, male-inclusive and non-cumulative entitlement would place Australia among the more comprehensive regimes, and the inquiry's 2026 report could establish a design template that other federal systems examine closely.

The core message is straightforward. Reproductive health events are predictable, common and currently managed through concealment and rationed sick leave, at a cost borne by workers and, through presenteeism, by employers. A dedicated paid entitlement, additional to sick leave and supported by flexible arrangements, addresses both.

The inquiry has the evidence, the precedent and the testimony; what remains is the calibration that turns principle into workable national policy.